FMS mutations in myelodysplastic, leukemic, and normal subjects

Area of Science:

• Molecular Biology
• Oncology
• Hematology

Background:

• The FMS gene encodes a receptor crucial for macrophage and monocyte growth.
• Mutations in FMS, especially at codons 301 and 969, are implicated in cancer development.
• Codon 301 mutations may cause ligand-independent receptor activity, while codon 969 mutations disrupt negative regulation.

Purpose of the Study:

• To investigate the frequency of FMS gene point mutations at codons 969 and 301 in human myeloid malignancies.
• To determine if these mutations are somatic or constitutional and their association with specific myeloid cancer types.

Main Methods:

• Analysis of DNA from 110 patients with myelodysplasia (MDS) and acute myeloblastic leukemia (AML).
• Sequencing of codons 969 and 301 of the FMS gene.
• Comparison of mutation frequencies across different myeloid malignancies and in normal subjects.

Main Results:

• A 12.7% incidence of codon 969 mutations and a 1.8% incidence of codon 301 mutations were found in patients.
• Mutations were more common in chronic myelomonocytic leukemia (20%) and AML type M4 (23%).
• Somatic origin of mutations was suggested by their appearance at different disease stages.

Conclusions:

• FMS gene mutations are prevalent in human myeloid malignancies, particularly those with monocytic features.
• The presence of these mutations may be linked to the development of myeloid cancers.
• A constitutional mutation at codon 969 in a normal subject suggests a potential predisposition marker for myeloid malignancy.